US 9855330
Granulysin in immunotherapy
granted A61KA61K2039/55516A61K2039/55522
Quick answer
US patent 9855330 (Granulysin in immunotherapy) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Jan 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 4
- CPC classes
- A61K, A61K2039/55516, A61K2039/55522, A61K2039/55527, A61K2239/57